Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics (CORT) – Form 4 filing dated 7/3/2025
Chief Development Officer William Guyer reported a very small, Rule 10b5-1 governed transaction on July 1, 2025:
- Option exercise: 100 shares at an exercise price of $21.65.
- Open-market sale: 100 shares at an average price of $73.505.
- Post-transaction ownership: 5,487 common shares held directly and 389,900 option rights remaining.
The sale represents less than 2% of Guyer’s direct equity stake and is immaterial relative to Corcept’s 109 million basic shares outstanding. Because the trade was executed under a pre-arranged 10b5-1 plan adopted on 11/27/2024, it is generally viewed as routine and not a signal of changing fundamentals.